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maximum likelihood techniques assumes that the likelihood
function is Gaussian while in these analyses the likelihood
function, and the consequent error limits, are highly
asymmetrical. In order to estimate the upper and lower
confidence limits on the asymptotic prevalence it is therefore
necessary to vary the asymptote, maximise the likelihood
function by varying the other two parameters, Po and (, and
use a likelihood ratio test to find critical values
corresponding to upper and lower bounds for 95%
confidence limits.
Appendix 3. In order to obtain a functional form for the
age-prevalence data, we note that the probability that a
susceptible individual becomes infected at any time is
proportional to the force of infection, A, multiplied by the
overall population prevalence. Consider then a person
whose age is a1 at time t1 . The probability that this person
would have been infected at age a (assuming they were not
already infected) is
p(a) = AP (t1 - a1 + a) =Acer{t1- a1 + a)
where pet) is the prevalence at time t, and c and ( are
chosen to match the change in overall prevalence with time.
If we also let sexual activity decline exponentially from 1 at
age aO at a rate s, equation 2 becomes
p(a) = AP (t - a1- ale -5(a - aol·
Then, counting in time increments of 8t, the probability of
not being infected between ages aO and a" is:
q = (1 - Acii 8t)(1 - Acerte{r - 5)8t 8t) ...(1 _ Acert"""e{r - s)(a1 - ao)8t)
where t = t - (a1 - aO)' so that
In(q) =-Acert 8t(1 + e{r- 5)8t +...+ e(r- s){a1 - ao).
Summing the series gives
In(q) = Acert (1 - e(r - s){a1 - aO)/(( - s)
and the probability that an individual of age a is infected at
time t is p = 1 - q.
More sophisticated models would use a logistic form for
the time dependence of the prevalence and include the
distribution of the relative ages of sexual partners. However,
the present data fit this simple model reasonably well and
do not warrant the use of more extensive models.
We thank Ronelle Swanevelder for her comments on the
manuscript and would especially like to acknowledge the vital
role that she played in supervising and analysing the antenatal
clinic survey data.
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A pharmaco-economic study based on a
meta-analysis
Fran'rois Wessels, A Nixon Anderson,
Osman Ebrahim
Objectives. A retrospective analysis was conducted to
assess the cost-effectiveness of four intravenous
antibiotic treatment regimens in the treatment of severe
community-acquired pneumonia (CAP) in adults in a
private hospital setting. The study compared some third-
generation cephalosporin regimens with a second-
generation cephalosporin and an amoxicillin/c1avulanic
acid (co-amoxiclav) regimen to investigate published
South African treatment guidelines from a pharmaco-
economic point of view.
Method. A phanmaco-economic model of local costs,
from a payer perspective, was based on the results of a
meta-analysis of clinical papers from peer-reviewed
journals. The study compared intravenous (IV) ceftriaxone
(2 g once daily), cefotaxime (IV 2 g 3 times a day),
cefuroxime (IV 750 mg 3 times a day, followed by 500 mg
orally 3 times a day) and amoxicillin/c1avulanic acid
(IV 750 mg 3 times a day, followed by 625 mg orally 3
times a day).
Results. An analysis of the odds ratios (ORs) of all two-
way comparisons indicated that ceftriaxone ensured
significantly higher probabilities of successful outcomes
than the other antibiotic treatment regimens (ORs in the
order of two were indicated). The phanmaco-economic
results suggested that the ceftriaxone treatment regimen
was the most cost-effective in the hospital treatment of
CAP in adult patients. These results proved to be robust
across sensitivitj analyses for success rates and
treatment days. A sensitivity analysis testing the
assumption that patients could be discharged once the
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oral treatment was initiated indicated that the
amoxicillin/c1avulanic acid and cefuroxime treatment arms
were more cost-effective. The clinical validity of such an
assumption is questionable.
Conclusion. Despite the conservative approach followed
in terms of ceftriaxone data, both the clinical results and
cost-effectiveness supported the use of ceftriaxone in the
treatment of CAP in adults in the hospital setting.
S Afr Med J 1998; 88: 251-255.
Community-acquired pneumonia (CAP) is a world-wide
problem with high mortality and morbidity rates.' In a
country such as the USA, the mortality rate for CAP ranges
from 10% to 25%.1 CAP is the only infective disease
consistently among the top 10 causes of death in both the
First World and the developing countries. Pneumonia
accounted for approximately 5% of all deaths in patients
older than 65 years in South Africa during 1984.'-' It is
therefore clear that this condition not only impacts upon
personal health but, because of the high morbidity and
mortality rates, also adversely affects community life and
productivity. Mortality is, however, improved by the early
initiation of treatment with antibiotics to which the causative
organism is susceptible, and adversely affected by delayed
or inappropriate initial therapy!
A major cost in the treatment of patients with CAP is the
antibiotic regimen. In an effort to promote the cost-effective
treatment of the disease, the Pulmonology Society of South
Africa has laid out guidelines for the management of CAP!
The aim of this study was to evaluate the economic
implications of introducing third-generation cephalosporins
into the treatment of CAp, using the guidelines as a
benchmark or treatment reference scenario. The focus was
explicitly defined as adult patients with CAP treated in
private hospitals. The study was therefore limited to severe




A meta-analysis of published data on CAP was conducted
according to a pre-determined protocol following the
recommendations of Mulrow.s Four treatment arms were
planned for the study, reflecting the above guidelines and
introducing third-generation cephalosporins for comparative
purposes.
These arms consisted of: (I) intravenous (IV) amoxicillin/
clavulanic acid (co-amoxiclav) (sequential treatment
consisting of 750 mg 3 times a day and 625 mg orally 3
times a day), plus an oral macrolide; (it) cefuroxime (IV 750
mg 3 times a day followed by 500 mg orally 3 times a day);
(iiJ) cefotaxime (IV 2 g 3 times a day); and (iv) ceftriaxone
(IV 2 g once daily). These doses are generally reported in the
literature, and are therefore considered to be comparable.
Severity has been considered to be comparable if patients
were treated with an intravenous antibiotic regimen in a
hospital setting.
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In view of the unavailability of published data on the
combination therapy, the first treatment arm was changed to
only amoxicillin/c1avulanic acid. This was not considered a
serious loss in terms of representativeness and usefulness
of the study results, because it still reflects clinical practice
of the hospital treatment of pneumonia in many cases. The
meta-analysis formed the clinical basis for the study and
was followed by a costing exercise, quantifying the clinical
results in terms of South African prices. This added an
economic perspective and local content to the study.
Methods and assumptions
Literature search
A MEDLlNE search for published papers was conducted
and supplemented by Internet database searches. The key
words used included 'community-acquired pneumonia',
'CAP,' 'adults', 'hospital', and the different drug names.
Mostly English papers were assessed, although one German
paper was considered but was judged inappropriate.
Inclusion criteria
Predetermined inclusion criteria for pUblished papers,
used to establish their suitability for the study, were
established and included the following:
1. Papers that reported randomised, controlled trials.
Blinding was not included as a selection criterion. This was
considered impractical, as some treatment arms included
oral agents while others contained only IV administered
drugs.
2. Studies stating a clear diagnosis and including clinical
success rates, defined as clinical cure or improvement.
Papers reporting on lower respiratory tract infections were
scrutinised and those actually reporting pneumonia or
containing subgroups of CAP patients were included, with
CAP-specific data being extracted. Severity was considered
as one of the criteria determining the combinability of the
data.
3. Clinical trials reporting results of treatment with the
specified dosages and formulations of the study drugs.
4. For inclusion of a treatment arm into the stUdy, more
than one clinical trial was required. This requirement was
lifted in the case of amoxicillin/c1avulanic acid because the
sample size (256 patients in each arm) reported by Brambilla
et al. 6 was considered sufficient to justify inclusion.
Unfortunately, no threshold sample size or proportion of
patients diagnosed with CAP could be imposed on the
inclusion criteria. The number of papers available did not
allow the inclusion criteria to be so conservative. Treatment
days were also not included as an inclusion criterion, but a
treatment arm could not be included in the study design if
no data on length of treatment were available.
Exclusion criteria
Similarly, exclusion criteria were established and included:
1. Any trial not stating the specific diagnosis of CAP.
Some pharmaco-economic studies failed in thiS respect and
were excluded because they could potentially introduce
bias.
2. Studies dealing with nosocomial pneumonia,
bronchitis, immunosuppressed patients, only paediatric
patients, and ambulatory treatment settings. Given the focus
I
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of this current study, treatment in intensive care facilities
was not considered valid for inclusion.
Results
Fig. 1. Odds ratios.
Statistical and meta-analysis
Applying the inclusion and exclusion criteria reported above,
21 papers were identified from the literature as being
relevant to the study.'·2.6-24 From these papers, data from five
clinical trials contained results that passed the homogeneity
test and were therefore used for the meta-analysis. The
results are reported in Table I. The data obtained from the
meta-analysis were used to calculate the ORs for all the
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Barradas et al." 19 2
Aggregate 65 5
Cefotaxime**





Brambilla et al.' 223 33
Siegel et al'"3 18 2
Aggregate 241 35
Amoxicillin/clavulanic acid
Brambilla et ai' 220 36
. x' 0.26; P 0.6126; NS.
.• x' 3.43; P 0.1799; NS.
.- x' 0.14; P 0.7083; NS.







Apart from the above qualitative criteria, statistical
methods were employed to test the homogeneity of the
data. A chi-square test with a priori significance level (alpha)
of 5% was performed on the data from all appropriate trials
for each drug. Only once it was proved in this way that the
results were not trial-dependent and could therefore be
combined were they included in the meta-analysis and
aggregated. The success rates and treatment days for each
treatment arm were calculated to be the weighted average
of those reported in the relevant trials.
The aggregated data were described and analysed by
reporting the odds ratio (OR) for every two-way comparison
of drugs. The OR reports the relative odds of observing a
specific outcome in a particular treatment scenario. This
study sought to determine the relative odds of observing a
satisfactory outcome (clinical cure or improvement) in one
experimental drug compared with another. An OR greater
than unity implies that it is more likely to observe a
satisfactory outcome in the experimental drug than in the
control drug. ORs less than unity refer to satisfactory
outcome less likely to occur in the experimental group and
unity implies no significant difference between the two
treatment groups. Ninety-five per cent confidence intervals
(Cls) for the ORs were calculated. If a 95% Cl for the OR
includes unity, it will indicate that there is no significant
difference between the two comparators, tested at the 5%
level of significance.
Pharmaco-economic analysis
The perspective of the pharmaco-economic analysis is
that of the consumer/payer of health care services. The
comparison was done by costing out the scenarios reported
in the clinical trials, making use of South African private
sector hospital prices and Representative Association of
Medical Schemes Scale of Benefits rates where applicable.
The charges taken into consideration were drug prices,
administration costs and ward costs. The consumables used
in IV drug administration included the peripheral line (Jelco
cannula, intravenous line, buretrol and IV fluids, where
applicable, and assumed to be replaced every 3rd day) and
drug reconstitution (two syringes, one needle and two
webcols). Ward costs have been calculated to the nearest
half day. The clinical success rates calculated in the meta-
analysis were used to determine the cost per successfully
treated patient. Discounting was not taken into
consideration because of the short duration of therapy and
the fact that adverse reactions were not included in the
study. Sensitivity analyses were performed on success
rates, treatment days and ward costs, recalculating the
results by making use of best-case scenarios as sourced
from the literature. Assumptions about ceftriaxone were not
varied in the sensitivity analyses and as a result, all
scenarios were tested against the same reference value.
For the sensitivity analysis on ward cost, it was assumed
that the oral phases of treatment of cefuroxime (axetil) and
amoxicillin/c1avulanic acid would not require hospitalisation.
This assumption was tested across the number of hospital
days.
I
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As is clear from this figure, the Gls of the GRs of all
comparisons involving ceftriaxone do not include unity, thus
indicating statistically significant differences. The GRs for
these comparisons are all in the order of 2, suggesting that
it is twice as likely to obtain a favourable outcome using a
2 g once-a-day IV ceftriaxone treatment regimen as in any of
the other comparator regimens considered.
Pharmaco-economic analysis
The fact that the statistical analysis suggested significant
differences between ceftriaxone and the other comparators
justified a cost-effectiveness analysis. If this had not been
indicated, the cheapest regimen would also have been the
most favourable pharmo-economic option. The results of the
pharmaco-economic analysis are reported in Table 11. As is
evident from these results, amoxicillin/clavulanic acid
treatment represents the cheapest regimen in terms of drug
costs. This trend is continued when administration costs are
included to given total drug delivery costs. However, when
ward costs are calculated and added to the drug delivery
costs, ceftriaxone treatment becomes the more suitable
option. The cost-effectiveness analysis, calculated as the
cost per satisfactory outcome (the ratio of total treatment
costs and success rate), clearly indicates that the
ceftriaxone regimen is the most cost-effective of the
treatment arms considered. The most significant difference
is observed between the two third-generation
cephalosporins, ceftriaxone and cefotaxime. The difference
between the other two treatment regimens does not appear
to be economically significant.
Table 11. Cost comparison between the four treatment arms
Arnoxicillin/
clavulanic
Cost analysis Ceftriaxone Cefotaxime Cefuroxime acid
Drug - IV R252.27 R416.97 R118.09 R125.51
Drug - oral R35.71 R30.28
Treatment days - IV 4.20 5.90 2.46 2.50
Treatment days - oral 5.22 5.00
Total drug (D) R1 059.54 R2 460.10 R476.93 R465.18
Admin - IV (A) R165.19 R189.19 R94.60 R94.60
Total drug delivery R1 224.72 R2 649.30 R571.53 R559.77
costs (0 +A)
Ward charges 0NJ R2 065.95 R2754.60 R3672.80 R3443.25
Total (0 +A + W) R3290.67 R5403.90 R4244.33 R4003.02
Success rate 92.86% 85.70% 87.30% 85.94%
Cost per successfully R3543.80 R6305.60 R4861.78 R4658.06
treated patient
Sensitivity analyses
The results obtained from the pharmaco-economic
analysis were tested for robustness across the assumptions
made. To this effect, sensitivity analyses were performed for
the success rates, treatment days and ward costs. The
results are presented in Table Ill. In the analysis that tested
success rates, the best success rates reported in the
literature for cefotaxime, cefuroxime and
amoxicillin/c1avulanic acid were compared with the meta-
analysis results for ceftriaxone. The results proved robust
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across these success rates, with the most favourable
outcome still being associated with the ceftriaxone
treatment arm. The difference between the cefotaxime and
the cefuroxime and amoxicillin/clavulanic acid treatment
arms became smaller in magnitude. When the most
favourable treatment periods for cefuroxime and
amoxicillin/clavulanic acid were used, the pharmaco-
economic results were again robust and no significant
changes were effected.




Ceftriaxone Cefotaxime Cefuroxime acid
Success rate
Meta-analysis' 92.86%
Best-caset 91.90% 90.00% 85.94%








Cost R 3.543.80 R 6 304.86 R 1 968.94 R 1 986.88
• Resu~s obtained from the meta-analysis of the published literature.
t Best-case scenarios published in the literature.
l Cost per successfully treated patient.
The sensitivity analysis on ward costs involved the
assumption that switching a patient from parenteral to oral
treatment implied that the patient would also be discharged
from hospital. This sensitivity analysis effected the only
significant change in the results and suggested an
advantage to parenteral/oral treatment regimens over those
involving only parenteral treatment. The analysis showed a
significant difference between the third-generation
cephalosporins and the other two treatment arms.
Gefotaxime was still almost twice as costly as ceftriaxone,
but the latter was more than 75% more costly than
cefuroxime or amoxicillin/c1avulanic acid. It must be noted,
however, that the success rates for the cefuroxime and
amoxicillin/c1avulanic acid arms reported in the literature
referred to patients hospitalised for the full duration of
treatment. The success rates for patients discharged once
they were put on oral therapy may be lower than those
reported, because of factors such as compliance and quality
of care. To explore the sensitivity of the analysis to ward
costs further, the number of hospital days were varied
across the range from 2 to 10 days. Fig. 2 indicates that at a
total of between 5 and 6 treatment days, the cefuroxime and
amoxicillin/clavulanic acid treatment arms are equivalent to
the ceftriaxone treatment in terms of cost-effectiveness.
Considering the severity of illness in the patients
investigated, this length of hospital treatment seems to
represent a likely scenario from a clinical perspective. The
findings from this sensitivity analysis strengthen the case for
outpatient parenteral antibiotic treatment.
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applicability of the data to South African conditions was
raised with clinicians. In a personal communication with
Professor Keith Klugman of the South African Institute of
Medical Research, he indicated that generally the same
pathogens would be involved in the cases of CAP
diagnosed in South Africa as in the papers used for the
meta-analysis, justifying the use of published data as clinical
basis for the study. However, the implications of this study in
making comparisons between various antibiotic regimens for
the treatment of CAP are sound and it is important to be
aware of all hidden costs when making prescribing
decisions about antibiotics of similar efficacy and tolerability.
We thank Juan Scribante, lnge Jenkinson, Ben Rust, Leon
Regensberg and Keith Kropman for their advice and assistance
during the study. Financial support for the study was provided
by Roche Products (Pty) Ltd.
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Fig. 2. Sensitivity analysis for hospital days (*at meta-analysis
hospital treatment period).
Conclusion
The demands on health care systems in South Africa have
increased dramatically in the last few years and have
precipitated increasing concern by decision-makers to
achieve value for money in many areas of health care. This
has led to appreciation of the need for the evaluation of the
true resource implications of many practices, including the
use of antibiotics in the management of CAP. The
pharmaco-economic analysis presented above and based
on published data indicated a distinct advantage for
ceftriaxone over the other antibiotic regimens for this
disease. These findings were reasonably robust across most
assumptions, the only exception being the impact of ward
costs. If one is to assume that patients who are switched to
oral treatment can be discharged immediately, the more
traditional treatment regimens were identified as more cost-
effective. However, this is probably not the case in most
practical settings. This assumption will have to be tested to
validate the representativeness of the scenario created in
this way.
The phanmaco-economic analysis only considered drug
prices, administration charges limited to consumable
products, and ward charges. The actual time of preparing
and administering the intravenous agents was not
investigated and has therefore not been costed out. This is
considered to be a limitation of the study. The cost of
treatment failure has also not been considered in the
analysis because no data on this aspect of the treatment of
CAP have been published. As is the case for nursing
administration time, a prospective trial will have to be
launched to collect data on the cost of treatment failure.
In this stUdy the results of the meta-analysis indicated that
ceftriaxone resulted in a significantly higher likelihood of
successful outcome in the parenteral treatment of
hospitalised patients with CAP. Some concern about the
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